Epigenetic Reprogramming in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The demonstration of induced pluripotency and direct lineage conversion has led to remarkable insights regarding the roles of transcription factors and chromatin regulators in mediating cell state transitions. Beyond its considerable implications for regenerative medicine, this body of work is highly relevant to multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies. Here, we review conceptual parallels between the respective biological phenomena, highlighting important interrelationships among transcription factors, chromatin regulators, and preexisting epigenetic states. The shared mechanisms provide insights into oncogenic transformation, tumor heterogeneity, and cancer stem cell models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Cited by
Items 501–600 of 702
Reid, M. A., Sanderson, S. M., & Locasale, J. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00009-8 · Cited by 13
Ueda, T., Ito, S., Shiraishi, T., Taniguchi, H., Kayukawa, N., Nakanishi, H., Nakamura, T., Naya, Y., Hongo, F., Kamoi, K., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.008 · Cited by 7
Huo, J. S., Baylin, S. B., & Zambidis, E. T. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.09.008 · Cited by 7
Application of mixed peptide arrays to study combinatorial readout of chromatin modifications
Mauser, R., Kungulovski, G., Meral, D., Maisch, D., & Jeltsch, A. (2017) · Biochimie · doi:10.1016/j.biochi.2017.11.008 · Cited by 7
DNA hydroxymethylation of colorectal primary carcinoma and its association with survival
Zhong, A., Tian, Y., Zhang, H., & Lai, M. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.24978 · Cited by 8
“Epigenetic factors like DNA methylation and histone modification have been found to contribute to cancer formation and progression.(7) Some studies of large groups of colon cancer patients have shown globally low or high levels of DNAmethylation inspecificpromoter regions.”
BackgroundMetabolic control of epigenetic rearrangements in B cell pathophysiology
Calciolari, B., Scarpinello, G., Tubi, L. Q., Piazza, F., & Carrer, A. (2022) · Open Biology · doi:10.1098/rsob.220038 · Cited by 8
“Chromatin is a highly plastic structure that dynamically changes during the cell cycle and across phenotypic states [50,51].”
BackgroundWu, P., Liu, Z., Zheng, L., Du, Y., Zhou, Z., Wang, W., & Lu, C. (2025) · Communications Biology · doi:10.1038/s42003-025-07954-8 · Cited by 11
“The comprehensive list of all signi fi cant reg-ulatees was provided in Supplementary Data 3.”
InfluentialAnand, A., Petersen, J. K., Andersen, L. V. B., Burton, M., Oudenaarden, C., Larsen, M. J., Erichsen, P. A., Pedersen, C. B., Poulsen, F. R., Grupe, P., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf071 · Cited by 6
Rashid, N. U., Sun, W., & Ibrahim, J. G. (2013) · Journal of the American Statistical Association · doi:10.1080/01621459.2013.869222 · Cited by 8
“The functions of these TFs, together with the involvement of H3K36me3 in cancer-related processes imply interesting connections between chromatin modification and tumorigenesis, a theme that is attracting increasing interest recently [Suvà et al., 2013].”
BackgroundThe downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior
Bornachea, O., López-Calderón, F., Dueñas, M., Segrelles, C., Lorz, C., Suárez-Cabrera, C., Marañón, M., Paradela‐Dobarro, B., Santos, M., & Paramio, J. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4353 · Cited by 7
“Accordingly, cancer cells present some remarkable similarities with embryonic stem cells, including unlimited proliferation and self-renewal, and the expression of pluripotency genes, such as NANOG, OCT4 or SOX2 [48].”
BackgroundInfluentialAndrews, E. H., Wang, Y., Xia, T., Cheng, W., & Cheng, C. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005340 · Cited by 6
Sulaiman, A., McGarry, S., El‐Sahli, S., Li, L., Chambers, J., Phan, A., Al‐Kadi, E., Kahiel, Z., Farah, E., Ji, G., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000123 · Cited by 8
Hossam, N., Matboli, M., Shehata, H. H., Aboelhussein, M. M., Hassan, M. K., & Eissa, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1816136 · Cited by 7
Liu, W., Zhang, X., Wen, Y., Anastasio, M. A., & Irudayaraj, J. (2023) · Environmental Advances · doi:10.1016/j.envadv.2023.100344 · Cited by 6
Barsotti, A. M., Ryskin, M., & Rollins, R. A. (2015) · Epigenomics · doi:10.2217/epi.15.27 · Cited by 7
Reprogramming Can Be a Transforming Experience
Hobbs, R. M., & Polo, J. M. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.02.003 · Cited by 6
“Many previous reports have linked individual iPSC reprogramming factors to tumor development to varying extents (Suvà et al., 2013).”
BackgroundFundamentally low reproducibility in molecular genetic cancer research
Алексеенко, И. В., Pleshkan, V. V., MONASTYRSKAYA, G. S., Kuzmich, A. I., Snezhkov, E. V., Didych, D. A., & Sverdlov, E. D. (2016) · Russian Journal of Genetics · doi:10.1134/s1022795416070036 · Cited by 6
“The cancer epigenome is also variable, as well as genomes of malignant tumors [75, 92, 93].”
BackgroundTian, W., Li, Y., Zhang, J., Li, J., & Gao, J. (2018) · DNA and Cell Biology · doi:10.1089/dna.2017.4085 · Cited by 8
“Recent reports have indicated the involvement of epigenetic mechanisms throughout the occurrence and development of lung cancer (Marsden et al. , 2009; Suva et al. , 2013; Leipold et al. , 2015; Tomasetti et al. , 2017).”
Epigenetic biomarkers in personalized medicine
Kronfol, M. M., & McClay, J. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814259-2.00015-7 · Cited by 12
Wang, Z., Embaye, K. S., Yang, Q., Qin, L., Zhang, C., Liu, L., Zhan, X., Zhang, F., Wang, X., & Qin, S. (2021) · Aging · doi:10.18632/aging.203315 · Cited by 6
“Epigenetic dysregulation is considered as an essential hallmark in the initiation and progression of different types of cancers [10, 11].”
BackgroundAre dietary factors involved in the association of CDH4 methylation and breast cancer risk?
Zhang, N., Li, L., Long, Z., Du, J., Li, S., Yin, H., Xie, K., Wu, Z., Chen, Y., Daria, V., et al. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521002804 · Cited by 6
“The malignant transformation of normal cells is analogous to somatic cell reprogramming, and the malignant transformation yields cells with unlimited self-renewal potential (5) .”
BackgroundZheng, Y., Luo, L., Lambertz, I. U., Conti, C. J., & Fuchs‐Young, R. (2022) · Cells · doi:10.3390/cells11162558 · Cited by 6
Kumar, A., Upadhyay, V., Lokhande, K. B., Swamy, K. V., Bhonde, R. R., Sarode, S. C., & Sharma, N. K. (2023) · Biomedicines · doi:10.3390/biomedicines11030889 · Cited by 6
Cancer stem cells and addicted cancer cells
Logtenberg, M. E. W., & Boonstra, J. (2013) · Oncology Discovery · doi:10.7243/2052-6199-1-7 · Cited by 8
Cellular analysis of the action of epigenetic drugs and probes
Hau, M., Zenk, F. L., Ganesan, A., Iovino, N., & Jung, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1274472 · Cited by 7
“Histone PTMs can show altered profiles in cancer cells or after drug treatment.(42) Chromatin immunoprecipitation (ChIP) is an invaluable method for studying interactions between specific proteins or modified forms of proteins and a genomic DNA region.”
BackgroundRecent advances in computational epigenetics
Ruskin, H. J., & Barat, A. (2017) · Advances in Genomics and Genetics · doi:10.2147/agg.s115524 · Cited by 7
“Considerable emphasis is also given in the literature to abnormal DNA methylation and hypermethylation of CpG islands situated close to promoter regions, as well as concomitant methylation of multiple loci, with strong indications that downregulation of expression of core genes results, together with distinctive pheno…”
BackgroundRomeo, M. A., Montani, M. S. G., Benedetti, R., Garufi, A., D’Orazi, G., & Cirone, M. (2020) · Biomolecules · doi:10.3390/biom10040586 · Cited by 7
“Indeed, together with genetic changes, post-translational modifications, including acetylation of histones and non-histone proteins, play a key role in cancerogenesis [3].”
BackgroundDrits-Esser, D., Malone, M., Barber, N. C., & Stark, L. A. (2014) · The American Biology Teacher · doi:10.1525/abt.2014.76.6.3 · Cited by 6
Mining Massive Amounts of Genomic Data: A Semiparametric Topic Modeling Approach
Fang, E. X., Li, M., Jordan, M. I., & Liu, H. (2016) · Journal of the American Statistical Association · doi:10.1080/01621459.2016.1256812 · Cited by 6
“1 Epigenetic Regulators are Relevant to Many Tumor Types Epigenetic control of gene expression is emerging as a crucial contributor to tumorigenesis and metastasis (Suvà et al., 2013).”
BackgroundRosano, D., Sofyalı, E., Dhiman, H., Ivanoiu, D., Slaven, N., Hong, S. P., Rocca, A., Bravaccini, S., Ravaioli, S., Noberini, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440779 · Cited by 8
“…most of their methylation due to culture condition (Liu et al., 2016; Roulois et al., 2015) so we focused our attention on epigenetic modifications, a well-established barrier to phenotypic divergence (Suva et al., 2013)with ties to ET resistance (Magnani et al., n.d., 2013; Nguyen et al., 2015).”
BackgroundPashov, A. D., Puente, C. V. H., Ibrahim, S. M., Monzavi‐Karbassi, B., Makhoul, I., & Kieber‐Emmons, T. (2018) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0014 · Cited by 6
“(16) A consequence of reprogramming is that the tumor’s competing cells tap into the numerous mechanisms of metazoan cellular cooperation, which gives them a greater advantage when adapting to the microenvironment as compared with typical ‘‘parasites.’’”
Inhibition of lung tumorigenesis by transient reprogramming in cancer cells
Pedrosa, P., Zhang, Z., Nuñez-Quintela, V., Macías, D., Ge, J., Denholm, M., Dyas, A., Estévez‐Souto, V., Lado‐Fernández, P., Gonzalez, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07207-2 · Cited by 6
Shabanov, P. D., & Иванович, В. В. (2021) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf192145-174 · Cited by 5
Pádua, D., Figueira, P., Pinto, M., Maia, A. F., Peixoto, J., Lima, R. T., Pombinho, A. R., Pereira, C., Almeida, R., & Mesquita, P. (2023) · Cancers · doi:10.3390/cancers15174406 · Cited by 6
Raasch, K., Malecki, E., Siemann, M., Montilla‐Martinez, M., Heinisch, J. J., Müller, J., Bakota, L., Kaltschmidt, C., Kaltschmidt, B., Rosemeyer, H., et al. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12488 · Cited by 5
“small molecules useful for the manipulation of neuronal cell fate due to the conceptual parallels between regulation of epigenetic states during cancer and cell differentiation (5).”
BackgroundClassification of Colon Cancer Patients Based on the Methylation Patterns of Promoters
Choi, W., Lee, J., Lee, J.-Y., Lee, S.-M., Kim, D.-W., & Kim, Y. (2016) · Genomics & Informatics · doi:10.5808/gi.2016.14.2.46 · Cited by 5
“Researchers have found that epigenetic factors, such as DNA methylation and histone modification, also contribute to cancer formation and development [5].”
BackgroundAn Artificial CTCF Peptide Triggers Efficient Therapeutic Efficacy in Ocular Melanoma
Wen, X., Wang, H., Chai, P., Fan, J., Zhang, X., Ding, T., Jia, R., Ge, S., Zhang, H., & Fan, X. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.07.004 · Cited by 5
Kottaridi, C., Koureas, N., Margari, N., Terzakis, E. G., Bilirakis, E., Pappas, A., Chrelias, C. G., Spathis, A., Aga, E., Pouliakis, A., et al. (2015) · BioMed Research International · doi:10.1155/2015/756359 · Cited by 5
The Epithelial-to-Mesenchymal Transition (EMT), a Particular Case
Cebrià‐Costa, J. P., Millanes‐Romero, A., de Herreros, A. G., & Peiró, S. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.960770 · Cited by 6
“The EMT process is driven by a set of specific transcription factors (including SNAIL1, ZEB1/2, and TWIST)(44) and involves very extensive epigenetic reprogramming, similar to processes that occur during other cellular changes such as stem cell differentiation.(45) EMT inducers promote general chromatin reorganization…”
BackgroundMolecular Culprits Generating Brain Tumor Stem Cells
Oh, S.-Y., & Kim, H. (2013) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2013.1.1.9 · Cited by 9
“Interestingly, these reprogramming factors also appear to be up-regulated, either alone or together, in the CSCs of various solid tumors, including brain tumor [49,50].”
Li, L., & Zhang, P. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230324135330 · Cited by 5
He, Y., Li, W., Li, L., Yang, Y., Lu, Y., Pan, Y., Wáng, Q., Sun, Y., Xie, Y., Wu, M., et al. (2025) · Advanced Genetics · doi:10.1002/ggn2.202500035 · Cited by 4
Ren, L., Gao, C., Duren, Z., & Wang, Y. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa245 · Cited by 4
“Last, alterations in DNA methylation patterns have been implicated in embryo development and tumorigenesis in many studies [23-25].”
BackgroundKapsner, L. A., Завгородний, М. Г., Majorova, S. P., Hotz‐Wagenblatt, A., Kolychev, O. V., Лебедев, И. Н., Hoheisel, J. D., Hartmann, A., Bauer, A. S., Mate, S., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33681 · Cited by 4
“Abnormal alteration of the epigenome is a vital ingredient of the neoplastic state.(1) The accurate quantification of epigenetic alterations is indispensable both for the mechanistic understanding (reviewed in References 2 and 3) and from the diagnostic and therapeutic perspectives.”
BackgroundEpigenetik bei entzündlichen Systemerkrankungen
Ospelt, C., & Gay, S. (2014) · Der Internist · doi:10.1007/s00108-013-3373-x · Cited by 4
Genomic approach to translational studies in colorectal cancer
Cheasley, D. A., Jorissen, R. N., Liu, S., Tan, C. W., Love, C. G., Palmieri, M., & Sieber, O. M. (2018) · Translational Cancer Research · doi:10.21037/4524 · Cited by 7
“Both hypo- and hypermethylation occur early in tumorigenesis (189-196), and the average CRC genome carries thousands of methylation changes with marked impact on the cellular transcriptional program (197,198).”
BackgroundKumar, A., Nilednu, P., Kumar, A., & Sharma, N. K. (2017) · Tumor Biology · doi:10.1177/1010428317695951 · Cited by 4
Identification of Novel Molecules Targeting Cancer Stem Cells
Benoit, Y. D. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_22 · Cited by 4
Cao, M., Wang, L., Xu, D., Bi, X., Guo, S., Xu, Z., Chen, L., Zheng, D., Li, P., Xu, J., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.008 · Cited by 4
“CRs are crucial regulatory factors of epigenetics, which have important roles in many cellular events [68,69].”
Background(B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer
Salomoni, P., Flanagan, A. M., & Cottone, L. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01227-9 · Cited by 4
“As a result of the increasing cancer sequencing studies, accumulating evidence in the past two decades has shown that virtually all classes of chromatin-associated epigenetic enzymes are frequently altered in cancer [4], suggesting that they play a driving role [5].”
Shekhawat, J. K., Sharma, J., Choudhury, B., Purohit, P., Sharma, P., & Banerjee, M. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09714-z · Cited by 4
“In turn, hypermethylation of CpG islands in tumour suppressor and DNA repair gene promoter regions might contribute to carcinogenesis by suppressing gene expression [ 3 , 4].”
Nuclear Topology, Epigenetics, and Keratinocyte Differentiation
Hughes, M. W., Lu, W., & Chuong, C. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.261 · Cited by 4
CAME: identification of chromatin accessibility from nucleosome occupancy and methylome sequencing
Piao, Y., Lee, S. K., Lee, E.-J., Robertson, K. D., Shi, H., Ryu, K. H., & Choi, J.-H. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw785 · Cited by 5
Meng, F., Guo, F., Sun, Z., Wang, S., Yang, C., Wang, C., Zhang, W., Gao, Z., Ji, L., Feng, F.-K., et al. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.06.005 · Cited by 4
Glodek, A. M., Kubiczak, M., Walkowiak, G. P., Nowak‐Markwitz, E., & Jankowska, A. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.06.016 · Cited by 4
DNA Methylation in Chronic Myeloid Leukemia
Leo, E. (2016) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000118 · Cited by 4
“It drives the transcriptional silence of integral genes for cancer development and progression, including those controlling DNA repair, cell cycle, cell adhesion, apoptosis and angiogenesis [6].”
BackgroundCarlberg, C., & Molnár, F. (2018) · Springer eBooks · doi:10.1007/978-981-10-7614-5_10 · Cited by 4
Histone Recognition by WD40 Proteins
Wilson, J. R., & Justin, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-18102-8_4 · Cited by 4
“The copying of chromatin domains is needed to ensure the correct development of multicellular organisms, but often goes awry in diseases such as cancer (Albert and Helin 2009; Sharma et al. 2010; Suva et al. 2013).”
BackgroundCell identity and plasticity uncoupled
Stefano, B. D. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00943-7 · Cited by 4
Sareło, P., Kaczorowska, A., Gąsior‐Głogowska, M., Godkowicz, K., Lamperska, W., Drobczyński, S., Zioło, E., Licznerska, A., Wróbel, T., Podbielska, H., et al. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2560965 · Cited by 3
“26 Chromatin is a structure composed of DNA, histone proteins, and other macromolecules that are subject to several dynamic epigenetic modifications.”
The Potential of Noncoding RNAs-siRNAs in Cancer Research and Therapy: Challenges and Solutions
Himanshu, Bashir, M., Lone, M. R., & Maqbool, M. (2026) · Experientia supplementum · doi:10.1007/978-3-032-06948-1_5 · Cited by 4
Epigenetic maintenance of the injury response state in glioblastoma stem cells
Molaei, F., MacLeod, G. D. A. H., Haider, S., Tiffany, A. S., Oteng, F. M., Berman, J. M., Skirzynska, A., Shoichet, M. S., Schramek, D., Dirks, P. B., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag002 · Cited by 3
An NAD+ dependent/sensitive transcription system: Toward a novel anti-cancer therapy
Uchiumi, F., Sato, A., Asai, M., & Tanuma, S. (2020) · AIMS molecular science · doi:10.3934/molsci.2020002 · Cited by 4
The silent guardian: unraveling the roles of H3K9me3 in genome maintenance
Li, Z., & Zhang, Z. (2024) · Genome Instability & Disease · doi:10.1007/s42764-024-00131-x · Cited by 3
“In fact, epigenetic reprogramming is regarded as one of the hallmarks of cancer and targeting the cancer epigenome has emerged as a promising anti-tumor approach (Cheng et al., 2019; Davalos & Esteller, 2023; Hanahan, 2022; Suva et al., 2013; Zhao et al., 2021).”
Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management
Florian, I. Ş., & Șușman, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76205 · Cited by 4
“These experiments have led to the identification of six different subtypes, with a different clinical evolution [132].”
BackgroundTranscriptomic Analyses in Zebrafish Cancer Models for Global Gene Expression and Pathway Discovery
Huang, X., Agrawal, I., Li, Z., Zheng, W., Lin, Q., & Gong, Z. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-30654-4_7 · Cited by 3
Stein, G. S., Messier, T., Gordon, J. A. R., Boyd, J. R., Tye, C. E., Lian, J. B., & Stein, J. L. (2016) · Aging · doi:10.18632/aging.100940 · Cited by 3
Stem Cells and Asymmetric Cell Division
Sousa‐Nunes, R., & Hirth, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-27583-3_3 · Cited by 3
The Hitchhiker’s Guide across a Waddington’s landscape of melanoma
Marie, K. L., Merlino, G. T., & Day, C. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.10.005 · Cited by 3
Kozawa, S., Yokoyama, H., Urayama, K., Tejima, K., Doi, H., Takagi, S., & Sato, T. N. (2023) · Bioinformatics Advances · doi:10.1093/bioadv/vbad047 · Cited by 3
“The neoplasia can be regarded as a partial cellular reprogramming, as it is accompanied by the aberrant activations of large number of genes (Buganim et al., 2012; Suva et al., 2013; Ward and Thompson, 2012; Xing et al., 2020).”
BackgroundSøreide, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805388-1.00034-1 · Cited by 3
Most of transcriptional alterations in glioma result from DNA-methylation independent mechanismsPreprint
Court, F., Boiteux, E. L., Fogli, A., Müller-Barthélémy, M., Vaurs‐Barrière, C., Chautard, E., Pereira, B., Biau, J., Kémény, J., Khalil, T., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/516997 · Cited by 3
“This hypothesis is further supported by the observation that methyltransferases and demethylases that regulate H3K27me3 and H3K4me3 deposition, such as EZH2, the MLL family members and UTX, are translocated or mutated and/or their expression is altered in many malignancies (16,17).”
BackgroundSOX17 : a new therapeutic target for immune evasion of colorectal cancer
Das, A., Yilmaz, Ö. H., Yilmaz, O. H., & Deshpande, V. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209878 · Cited by 2
“58 67 68 Since oncogenes are believed to promote reprogramming, 69 another hypothesis states that the mutations in SOX17 convert it into a potent oncogene by converting it to a high-performance reprogramming factor.”
Lingasamy, P., Kiruba, B., Rajakumar, S., Surisetti, S. M., Patel, N., Sajitha Lulu, S., Salumets, A., & Modhukur, V. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119777 · Cited by 3
Replication-associated DNA damage in induced pluripotent stem cells
Vallabhaneni, H., & Hursh, D. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99892-5.00023-2 · Cited by 2
Molecular genetic characteristics of colorectal cancer
Seferov, B. D., Grickevich, O. Y., Lazarev, A. E., Golubinskaya, E. P., & Maksimova, P. E. (2023) · Malignant tumours · doi:10.18027/2224-5057-2023-13-4-78-83 · Cited by 2
The R736H cancer mutation in DNMT3A modulates the properties of the FF-subunit interface
Kunert, S., Emperle, M., Adam, S., Bräcker, J., Brockmeyer, J., Rajavelu, A., & Jeltsch, A. (2022) · Biochimie · doi:10.1016/j.biochi.2022.12.005 · Cited by 2
Novel insights into DNA methylation-based epigenetic regulation of breast tumor angiogenesis
Bhat, S. M., Prasad, P. R., & Joshi, M. B. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.04.002 · Cited by 2
Targeted Combination Nanotherapeutics in Cancer a Real Promise
Shiekh, F. A., Mian, S. H., Arja, S. B., & Rao, M. R. (2015) · Nanomedicine · doi:10.2217/nnm.15.75 · Cited by 2
Drug discovery in academic institutions
Frye, S. V. (2013) · Hematology · doi:10.1182/asheducation-2013.1.300 · Cited by 2
Yang, T., & Yildirim, E. (2017) · Current Pathobiology Reports · doi:10.1007/s40139-017-0120-3 · Cited by 2
Precision Medicine Based on Next-Generation Sequencing and Master Controllers
Dukleska, K., Yeo, C. J., Pishvaian, M. J., & Brody, J. R. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_71 · Cited by 2
Mutations in Histone Lysine Methyltransferases and Demethylases
Weirich, S., & Jeltsch, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65056-0 · Cited by 2
The Role of Epigenetics in Pancreatic Ductal Adenocarcinoma
Roalsø, M. T. T., Hald, Ø. H., Ansari, D., Andersson, R. E., & Søreide, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_22 · Cited by 2
Colorectal Cancer Is Borrowing Blueprints from Intestinal Ontogenesis
Billingsley, J. L., Yevdokimova, V., Ayoub, K., & Benoit, Y. D. (2023) · Cancers · doi:10.3390/cancers15204928 · Cited by 2
“The emergence of CSCs in the early steps of carcinogenesis relies on the reprogramming of the epigenome, which is marked by changes in the activation state of key chromatin regulators re-wiring gene expression networks [5–7].”
BackgroundEpidermal Stem Cells in Orthopaedic Regenerative Medicine
Li, J., Zhen, G., Tsai, S., & Jia, X. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611626 · Cited by 2
“iPSCs currently face challenges with regards to biological safety including oncogenesis [93].”
BackgroundModulation of Cell State to Improve Drug Therapy
Gallo, J. M. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12317 · Cited by 2
“It is well appreciated that tumors consist of different cell types that possess a certain degree of plasticity.(1) Of particular interest is the transition between cancer stem cells and differentiated cancer cells that are linked to epigenetic reprograming.”
BackgroundP53 PROTEIN AND ITS FUNDAMENTAL ROLE IN THE CELL CYCLE, APOPTOSIS AND CANCER
Nepomuceno, L. L., Ferreira, J. L., Cruz, V. D. S., Gabriel, G., & de Araújo, E. G. (2018) · Enciclopédia Biosfera · doi:10.18677/encibio_2018b64 · Cited by 4
“In general, these changes activate oncogenes and inactivate tumor suppressor genes (SUVÀ et al., 2013).”
BackgroundWhere to Draw the LINE—Are Retrotransposable Elements Here to Stay?
Bergin, C. J., da Silva, A. M., & Benoit, Y. D. (2023) · Cancers · doi:10.3390/cancers15164119 · Cited by 2
Epigenetics technologies for personalized medicine
Singh, S., Chauhan, A., & Kumar, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23802-4.00025-9 · Cited by 1
siRNA-guided dual-targeting nanocarrier for breast cancer treatment
Kılıçay, E., Sahin, B., Karahaliloğlu, Z., Çelik, E., & Hazer, B. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2490041 · Cited by 1
“Cancer arises from a cascade of genetic mutations, including oncogene activation and tumour suppressor gene loss, leading to uncontrolled proliferation and impaired apoptosis (McLeod 2013, Suvà et al. 2013, Lee et al .”
m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis
Peng, J., Fu, X., Li, S., Hu, C., Zhao, X., & Peng, J. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0436 · Cited by 1
“This disease arises from mutations and chromosomal translocations that target various factors, including epigenetic regulators (3).”
Epigenetics and One-Carbon Metabolism in Cancer: Mechanisms and Therapeutic Implications
Serpa, J., & Costa, J. R. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_9 · Cited by 2
The pathoanatomy of cancer: order in paradox
Höckel, M. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106161 · Cited by 1
Changes in Cancer Stem Cell Signalling Pathways With Plant Metabolites to Discover Chemotherapy
Rizvi, A., Farhan, M., Ahmad, A. R., & Aatif, M. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71378 · Cited by 1
“The progeny cells usually lie in a semi-differentiated or a partially differentiated state, and may themselves give rise to distinctly identifiable sub-populations [3].”
Attempt at a systemic outlook on aging and carcinogenesis
Piwowar, M. W., Dygut, J. M., Piwowar, P., Konieczny, L., & Roterman, I. (2014) · Bio-Algorithms and Med-Systems · doi:10.1515/bams-2014-0012 · Cited by 1
“, methylation and improper ubiquitination, which are caused by mutations in genes associated with epigenetic mechanism rather than any metabolic pathways [85, 86].”
BackgroundPrinciples of Cancer Pathogenesis and Therapies: A Brief Overview
Dias, R. B., Valverde, L. D. F., Rocha, C. A. G., & Bezerra, D. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-19144-7_1 · Cited by 2
Molecular Basis of Colorectal Cancer: Tumor Biology
Ren, Z., & Zhang, T. (2018) · Springer eBooks · doi:10.1007/978-981-10-5143-2_3 · Cited by 3
Epigenetic-Processes Driven Disorders and Therapeutics
Thumoju, S., & Mohan, V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812215-0.00018-2 · Cited by 1
Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance
Raz, D. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_11 · Cited by 1
Metadata
- Authors
- Suvà, M. L., Riggi, N., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Corresponding author
- Suvà, Mario L.
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1567-1570
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3821556
- OpenAlex
- W2090757807
- Cited by
- 706
- References
- 64
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 19 · 2023: 40 · 2022: 34 · 2021: 61 · 2020: 62 · 2019: 48 · 2018: 58 · 2017: 72 · 2016: 67 · 2015: 76 · 2014: 85 · 2013: 43
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Environmental Health Sciences (U01ES017155)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic reprogramming, cancer, induced pluripotency, transcription factors, chromatin regulators, oncogenic transformation, tumor heterogeneity, cancer stem cells, cell state transitions
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chromatin, Humans, Neoplasms, Transcription Factors, Neoplastic Stem Cells, DNA Methylation, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.